New combo aims to outsmart prostate cancer without Long-Term hormone shots
Disease control
Completed
This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) — alone or with an injected immune stimulant called SD-101 — to standard radiation and short-term hormone therapy could better control prostate cancer that has spread to a few spots. Twenty-three men…
Phase: PHASE2 • Sponsor: David Oh • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC